KLP Kapitalforvaltning AS Increases Holdings in ADMA Biologics Inc $ADMA

KLP Kapitalforvaltning AS grew its holdings in ADMA Biologics Inc (NASDAQ:ADMA) by 7.3% during the 2nd quarter, Holdings Channel.com reports. The fund owned 49,700 shares of the biotechnology company’s stock after acquiring an additional 3,400 shares during the period. KLP Kapitalforvaltning AS’s holdings in ADMA Biologics were worth $905,000 at the end of the most recent reporting period.

Several other large investors have also made changes to their positions in ADMA. Cetera Investment Advisers increased its holdings in shares of ADMA Biologics by 1.3% in the first quarter. Cetera Investment Advisers now owns 50,511 shares of the biotechnology company’s stock worth $1,002,000 after purchasing an additional 670 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank increased its holdings in shares of ADMA Biologics by 1.1% in the first quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 66,671 shares of the biotechnology company’s stock worth $1,323,000 after purchasing an additional 711 shares during the last quarter. GAMMA Investing LLC increased its holdings in shares of ADMA Biologics by 15.5% in the second quarter. GAMMA Investing LLC now owns 7,613 shares of the biotechnology company’s stock worth $139,000 after purchasing an additional 1,024 shares during the last quarter. GF Fund Management CO. LTD. increased its holdings in shares of ADMA Biologics by 21.9% in the first quarter. GF Fund Management CO. LTD. now owns 6,053 shares of the biotechnology company’s stock worth $120,000 after purchasing an additional 1,089 shares during the last quarter. Finally, Journey Strategic Wealth LLC increased its holdings in shares of ADMA Biologics by 6.6% in the first quarter. Journey Strategic Wealth LLC now owns 17,820 shares of the biotechnology company’s stock worth $354,000 after purchasing an additional 1,102 shares during the last quarter. 75.68% of the stock is currently owned by hedge funds and other institutional investors.

ADMA Biologics Trading Up 0.9%

Shares of NASDAQ ADMA opened at $15.09 on Thursday. The company has a debt-to-equity ratio of 0.21, a quick ratio of 2.78 and a current ratio of 5.33. The business’s 50 day moving average price is $16.08 and its 200-day moving average price is $18.45. ADMA Biologics Inc has a fifty-two week low of $13.50 and a fifty-two week high of $25.67. The company has a market cap of $3.60 billion, a price-to-earnings ratio of 17.55 and a beta of 0.47.

ADMA Biologics (NASDAQ:ADMA) last issued its quarterly earnings results on Wednesday, August 6th. The biotechnology company reported $0.15 earnings per share for the quarter, topping the consensus estimate of $0.14 by $0.01. ADMA Biologics had a return on equity of 41.01% and a net margin of 44.06%.The firm had revenue of $121.98 million for the quarter, compared to the consensus estimate of $121.77 million. During the same period in the prior year, the business posted $0.13 earnings per share. The company’s revenue for the quarter was up 13.8% on a year-over-year basis. On average, sell-side analysts expect that ADMA Biologics Inc will post 0.51 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings restated a “buy (b-)” rating on shares of ADMA Biologics in a research report on Wednesday, October 8th. One analyst has rated the stock with a Strong Buy rating and three have given a Buy rating to the company’s stock. According to MarketBeat, ADMA Biologics presently has a consensus rating of “Buy” and an average target price of $27.67.

ADMA Biologics Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.